Sugi Predict

Sugi Predict / Compounds / SCHEMBL5384036

SCHEMBL5384036

SCHEMBL5384036

O=C(Nc1ccc(O)cc1)c1cccnc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 1/20 0.76
▸ ROCK1 Q13464 1/20 0.76
▸ LMNA P02545 1/20 0.73
▸ HIF1A Q16665 1/20 0.73
▸ RAB9A P51151 7/20 0.68
▸ NPC1 O15118 5/20 0.68
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ TP53 P04637 1/20 0.68
▸ KMT2A Q03164 3/20 0.67
▸ CYP3A4 P08684 1/20 0.67
▸ MEN1 O00255 2/20 0.65
▸ MAPT P10636 2/20 0.65
▸ GFER P55789 1/20 0.65
▸ NPSR1 Q6W5P4 1/20 0.65
▸ NAMPT P43490 1/20 0.65
▸ ALDH1A1 P00352 2/20 0.64
▸ GAA P10253 2/20 0.63
▸ TDP1 Q9NUW8 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ THRB P10828 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nicotinanilide SCHEMBL29067673 0.86 LMNA (0.83) ROCK2ROCK1LMNAHIF1ARAB9A
Nicotinanilide SCHEMBL352439 0.86 LMNA (0.83) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL14880208 0.86 ROCK2 (1.00) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL9031269 0.85 ROCK2 (0.73) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL1971026 0.85 NAMPT (0.78) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL29362556 0.85 ROCK2 (0.73) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL3093633 0.85 CYP3A4 (0.82) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL13363308 0.85 ROCK2 (0.73) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL10131874 0.85 ROCK2 (0.73) ROCK2ROCK1LMNAHIF1ARAB9A
SCHEMBL7329481 0.85 ROCK2 (0.73) ROCK2ROCK1LMNAHIF1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016102969-A1 INHIBITION OF HAIR GROWTH THE UNIVERSITY OF MANCHESTER (GB) 2016-06-30 — — WO claimed
WO-2016102969-A1 INHIBITION OF HAIR GROWTH THE UNIVERSITY OF MANCHESTER (GB) 2016-06-30 — — WO disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 — — US disclosed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 — — US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 — — CN disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 — — US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 — — US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 — — CN disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 — — US disclosed
CN-1543451-A Receptor modulators activated by peroxizonal proliferators (ppar) — 2004-11-03 — — CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 — — EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 — — US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 — — US disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 — — WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 — — WO disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 — — WO disclosed
EP-0091519-B1 TOPICAL ACYLAMINOPHENOLS Johnson & Johnson Products Inc. (US) 1987-06-24 — — EP disclosed
EP-0091519-A1 Topical acylaminophenols Johnson & Johnson Products Inc. (US) 1983-10-19 — — EP disclosed
US-4329366-A ANTIINFLAMMATORY AGENTS JOHNSON & JOHNSON PRODUCTS, INC. (US) 1982-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL ROCK2 3294/4885ROCK1 2994/4885LMNA 1410/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL ROCK2 3642/4885ROCK1 3518/4885LMNA 2068/4885
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA ROCK2 4474/4885ROCK1 4788/4885LMNA 3747/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA ROCK2 4526/4885ROCK1 4781/4885LMNA 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.